Effects of single-nucleotide polymorphism on the pharmacokinetics and pharmacodynamics of metformin
| Autor: | Shaoqian Li, Bo Xu, Shangzhi Fan, Bo Kang, Lijing Deng, Danjun Chen, Bo Yang, Fan Tang, Zunbo He, Yong Xue, Jie-Can Zhou |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Expert Review of Clinical Pharmacology. 15:1107-1117 |
| ISSN: | 1751-2441 1751-2433 |
| DOI: | 10.1080/17512433.2022.2118714 |
| Popis: | Metformin has been recognized as the first-choice drug for type 2 diabetes mellitus (T2DM). The potency of metformin in the treatment of type 2 diabetes has always been in the spotlight and shown significant individual differences. Based on previous studies, the efficacy of metformin is related to the single-nucleotide polymorphisms of transporter genes carried by patients, amongst which a variety of gene polymorphisms of transporter and target protein genes affect the effectiveness and adverse repercussion of metformin.Here, we reviewed the current knowledge about gene polymorphisms impacting metformin efficacy based on transporter and drug target proteins.The reason for the difference in clinical drug potency of metformin can be attributed to the gene polymorphism of drug transporters and drug target proteins in the human body. Substantial evidence shows that genetic polymorphisms in transporters such as organic cation transporter 1 (OCT1) and organic cation transporter 2 (OCT2) affect the glucose-lowering effectiveness of metformin. However, optimization of individualized dosing regimens of metformin is necessary to clarify the role of several polymorphisms. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|